Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 1Rectal Neoplasms 1Nausea 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × L 758298 × Clear all
NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

OHSU Knight Cancer Institute

Phase 2 Completed
54 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡